REGENXBIO (RGNX) reported second-quarter 2026 revenue of $108.0 million, up from $21.4 million a year earlier, and net income of $22.7 million, or $0.43 basic and diluted net income per share.
The company said it received more than $200 million in new capital in July 2026, including a $100 million AbbVie milestone payment and about $108 million in net public offering proceeds, extending expected cash runway into Q4 2027.
- Cash, cash equivalents and marketable securities were $105.5 million as of June 30, 2026.
- Pro forma cash, cash equivalents and marketable securities as of June 30, 2026, were approximately $313 million after July proceeds.
- REGENXBIO said RGX-202 BLA submission initiation for Duchenne muscular dystrophy remains on track for Q3 2026.
- Topline data from pivotal subretinal wet AMD studies ATMOSPHERE and ASCENT are expected in Q4 2026.
- The company plans to resubmit the RGX-121 BLA for Hunter syndrome in Q3 2026 after a July Type A meeting with the FDA.
$RGNX Insider Trading Activity
$RGNX insiders have traded $RGNX stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $RGNX stock by insiders over the last 6 months:
- STEVE PAKOLA (Chief Medical Officer) has made 0 purchases and 5 sales selling 78,927 shares for an estimated $939,970.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RGNX Hedge Fund Activity
We have seen 79 institutional investors add shares of $RGNX stock to their portfolio, and 78 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- QUBE RESEARCH & TECHNOLOGIES LTD added 867,803 shares (+196.0%) to their portfolio in Q1 2026, for an estimated $7,272,189
- ASSENAGON ASSET MANAGEMENT S.A. removed 811,332 shares (-82.7%) from their portfolio in Q2 2026, for an estimated $9,719,757
- STATE STREET CORP added 444,749 shares (+19.4%) to their portfolio in Q1 2026, for an estimated $3,726,996
- 22NW, LP removed 430,920 shares (-46.7%) from their portfolio in Q1 2026, for an estimated $3,611,109
- TWO SIGMA INVESTMENTS, LP added 424,951 shares (+327.0%) to their portfolio in Q1 2026, for an estimated $3,561,089
- ACADIAN ASSET MANAGEMENT LLC removed 372,166 shares (-99.1%) from their portfolio in Q1 2026, for an estimated $3,118,751
- AQR CAPITAL MANAGEMENT LLC removed 310,250 shares (-22.8%) from their portfolio in Q1 2026, for an estimated $2,599,895
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
